Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: celeryroot.com who wrote (26588)	11/18/1998 10:22:00 AM
From: J Stone	Read Replies (1) \| Respond to of 32384

To clarify my point about LGND mgmt's "behinds on the line"... For over half a year LGND management has been saying they expected 2 drugs to be FDA approved by the end of the year. The drugs have gotten the panel recommendations but now, as I understand it, the FDA will make sure all the i's are dotted and the t's crossed and the applications before granting approval. LGND management is supposed to be experienced in this process, so the expectation has been that if the panels recommended approval, actual FDA approval would shortly follow. Granted, LGND did not file the original ONTAK application, but they've been handling it for the past few months. I want management to be looking over the FDA's shoulder with a pen in hand in case the FDA says, "Here's an undotted 'i'", so LGND can dot it instantly. We, and the Market, have all been counting on 4th quarter FDA approval for Panretin Gel and ONTAK. If the FDA delays approval for Panretin because of an imcomplete application, I believe the stock will fall. JMHO Jeff